14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AGIO ranks #16801 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Agios Pharmaceuticals Stock Forecast NASDAQ:AGIO

$34.22 (-1.75%)

Volume: 986k

Closed: Dec 03, 2021

Hollow Logo Score: -6.256

Agios Pharmaceuticals Stock Forecast

$34.22 (-1.75%)

Volume: 986k

Closed: Dec 03, 2021

Score Hollow Logo -6.256
Which way will AGIO go? Request
Key Stats
P/E Ratio 1.16
Beta 0.76
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 5 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Agios Pharmaceuticals stock price down 1.75% on Friday
(Updated on Dec 03, 2021)


Sell candidate since 2021-11-17 Loss -13.74%

The Agios Pharmaceuticals stock price fell by -1.75% on the last day (Friday, 3rd Dec 2021) from $34.83 to $34.22. and has now fallen 4 days in a row. During the day the stock fluctuated 8.13% from a day low at $33.94 to a day high of $36.70. The price has fallen in 8 of the last 10 days and is down by -11.6% for this period. Volume has increased on the last day by 236 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 986 thousand shares were bought and sold for approximately $33.73 million.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($37.12) are considered to be a "second chance" to get out. According to the fan-theory $27.79 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Agios Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $35.56 and $42.82. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 02, 2021, and so far it has fallen -31.26%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $2.76 between high and low, or 8.13%. For the last week, the stock has had a daily average volatility of 4.44%.

Agios Pharmaceuticals is oversold on RSI14 (5). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Agios Pharmaceuticals stock A Buy?

Agios Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -6.256

Predicted Opening Price for Agios Pharmaceuticals of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$34.95 $34.22 (Undervalued)
Strong Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Dec 03, 2021 "Bank of America" gave "$54.00" rating for AGIO. The price target was changed from $34.76 to 0.2%.

Volatility and Risk
Daily Average Volatility: 4.44 %
Overall Risk: Very High High Medium Low Very Low
Volatility
4.44 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $34.83
Price: $34.22
No Support Found

AGIO Insider Trading Show all Trades

INSIDER POWER

1.538

Last 100 transactions
Buy: 457 441 | Sell: 297 434 (Shares)
Date Action Amount Person Type
Jun 21, 2021 Buy 1 777 Alenson Carman Common stock
Jun 21, 2021 Sell 1 777 Alenson Carman Common stock
Jun 21, 2021 Sell 1 777 Alenson Carman Stock option (right to buy)
Jun 18, 2021 Sell 48 493 Bowden Christopher Common stock
Jun 18, 2021 Sell 1 885 Bowden Christopher Stock option (right to buy)
Show all Insider Trades
INSIDER POWER

1.538

Last 100 transactions
Buy: 457 441 | Sell: 297 434 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 37.71 10.21 %
36.66 7.13 %
36.01 5.22 %
Current price: 34.22
Support 33.90 -0.94 %
33.25 -2.84 %
32.19 -5.92 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 37.37 9.21 %
35.62 4.09 %
34.83 1.78 %
Current price 34.22
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Agios Pharmaceuticals

Agios Pharmaceuticals Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic maligna... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT